Chiome Bioscience Inc. (JP:4583) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Chiome Bioscience Inc. has entered into an exclusive licensing agreement with Asahi Kasei Pharma for the development and commercialization of its anti-CX3CR1 antibody, PFKR. The deal includes an upfront payment of ¥200 million to Chiome and potential milestone payments up to ¥24.8 billion, along with royalties based on future sales.
For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue